Plasminogen Replacement Therapy for Congenital Plasminogen Deficiency

January 4, 2018

At Prometic Life Sciences we are committed to addressing unmet medical needs in rare diseases such as Congenital Plasminogen Deficiency (PLGD). Congenital PLGD is an inherited disorder passed on from generation to generation in which a person is born with two mutated genes, one from each parent. This is commonly referred to as an autosomal recessive pattern. It is caused by changes in the gene that gives instructions to make plasminogen (PLG).

For more information on PLGD, visit http://plasminogen.com/ 

Previous Article
Prometic to present new data on how plasminogen reduces acute lung injury at the american thoracic society’s 2017 international conference
Prometic to present new data on how plasminogen reduces acute lung injury at the american thoracic society’s 2017 international conference

Next Article
Prometic completes the filing of its plasminogen biologics license application (“BLA”) with the U.S. FDA
Prometic completes the filing of its plasminogen biologics license application (“BLA”) with the U.S. FDA